Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Arrhythmias Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Arrhythmias Overview | 8 | 1 |
| Pipeline Products for Arrhythmias Comparative Analysis | 9 | 1 |
| Arrhythmias Therapeutics under Development by Companies | 10 | 1 |
| Arrhythmias Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Arrhythmias Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Arrhythmias Products under Development by Companies | 15 | 1 |
| Arrhythmias Products under Investigation by Universities/Institutes | 16 | 1 |
| Arrhythmias Companies Involved in Therapeutics Development | 17 | 6 |
| Cynata Therapeutics Limited | 17 | 1 |
| Gilead Sciences, Inc. | 18 | 1 |
| Ono Pharmaceutical Co., Ltd. | 19 | 1 |
| Orion Oyj | 20 | 1 |
| SciFluor Life Sciences, LLC | 21 | 1 |
| SignPath Pharma Inc | 22 | 1 |
| Arrhythmias Therapeutics Assessment | 23 | 9 |
| Assessment by Monotherapy Products | 23 | 1 |
| Assessment by Target | 24 | 2 |
| Assessment by Mechanism of Action | 26 | 2 |
| Assessment by Route of Administration | 28 | 2 |
| Assessment by Molecule Type | 30 | 2 |
| Drug Profiles | 32 | 19 |
| aladorian sodium Drug Profile | 32 | 2 |
| Antisense Oligonucleotides to Activate hERG1 for Long-QT Syndrome Drug Profile | 34 | 1 |
| efsevin Drug Profile | 35 | 1 |
| eleclazine Drug Profile | 36 | 2 |
| EU-8120 Drug Profile | 38 | 1 |
| GS-967 Drug Profile | 39 | 1 |
| KN-93 Drug Profile | 40 | 1 |
| landiolol Drug Profile | 41 | 1 |
| LH-021 Drug Profile | 42 | 1 |
| ORM-10103 Drug Profile | 43 | 1 |
| PP-1 Drug Profile | 44 | 1 |
| Small Molecule for Arrhythmia Drug Profile | 45 | 1 |
| Small Molecules to Antagonize Ryanodine Receptor 2 for Ventricular Arrhythmia Drug Profile | 46 | 1 |
| Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure Drug Profile | 47 | 1 |
| SPP-4040 Drug Profile | 48 | 1 |
| Stem Cell Therapy for Cardiovacular Diseases Drug Profile | 49 | 1 |
| VKII-86 Drug Profile | 50 | 1 |
| Arrhythmias Dormant Projects | 51 | 1 |
| Arrhythmias Discontinued Products | 52 | 1 |
| Arrhythmias Product Development Milestones | 53 | 1 |
| Featured News &Press Releases | 53 | 1 |
| May 09, 2014: Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome | 53 | 1 |
| Appendix | 54 | 2 |
| Methodology | 54 | 1 |
| Coverage | 54 | 1 |
| Secondary Research | 54 | 1 |
| Primary Research | 54 | 1 |
| Expert Panel Validation | 54 | 1 |
| Contact Us | 54 | 1 |
| Disclaimer | 55 | 1 |